BIOMARIN PHARMACEUTICAL INC awarded director Robert M Plenge 6,140 shares at $0 per share on Sep 10, 2026. The award left him with 6,140 shares, and the transaction represented about 100.0% of his resulting holding, giving investors the reported post-transaction ownership outcome.
Key Highlights
- Robert M Plenge held 6,140 BIOMARIN PHARMACEUTICAL INC shares after the transaction.
- The transaction represented about 100.0% of Plenge’s resulting shares holding.
- Transaction code A classified the entry as an award or grant.
BIOMARIN PHARMACEUTICAL INC (NASDAQ: BMRN) awarded director Robert M Plenge 6,140 shares at $0 per share. The transaction was recorded on Sep 10, 2026.
Director Award Recorded at Zero Cost
Transaction code A identifies the entry as an award or grant. The recorded price was $0 per share. Following the transaction, Plenge owned 6,140 shares of BIOMARIN PHARMACEUTICAL INC. The transaction represented about 100.0% of his resulting shares holding. Plenge is identified as a director of the company.
FAQs
Q: How many BIOMARIN shares did Robert M Plenge receive?
A: BIOMARIN PHARMACEUTICAL INC awarded director Robert M Plenge 6,140 shares on Sep 10, 2026. The filing reports a transaction price of $0 per share.
Q: What was Robert M Plenge’s resulting BMRN shareholding?
A: Plenge owned 6,140 BIOMARIN PHARMACEUTICAL INC shares after the transaction. That amount represented about 100.0% of his resulting shares holding.
Q: What does transaction code A mean for the BioMarin award?
A: Transaction code A identifies the transaction as an award or grant in the filing. The record dates this BioMarin award to Sep 10, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.